New York, February 26, 2026, 08:57 EST — Premarket
- CLDX dipped close to 4% in premarket action, changing hands at $29.58.
- The stock jumped 24% in the last session, closing out at $30.82.
- Investors are zeroing in on Celldex’s lineup of clinical updates slated for 2026.
Celldex Therapeutics dropped about 4% to $29.58 in premarket action Thursday, paring gains after the stock soared 24% to close at $30.82 the previous session.
This wasn’t about a headline move; the real action started when the timeline slipped. For clinical-stage biotechs, getting patients into late-stage trials quickly is everything—delays at this point can wreck a launch plan. That’s the risk investors tend to watch most closely.
What qualifies as “next” is getting redefined. Traders now anchor their bets more to fresh data releases and shifts in regulation rather than just watching trial enrollment figures. As a result, positioning often gets more cautious ahead of the next round of conference headlines.
Celldex finished enrolling patients for its two global Phase 3 barzolvolimab studies in chronic spontaneous urticaria (CSU) about half a year ahead of its own timeline. The biotech brought in 1,939 participants across more than 500 sites in 43 countries, according to the company. First data readout lands in the fourth quarter of 2026, and a U.S. BLA could follow in 2027. “The early completion highlights the significant unmet need,” CEO Anthony Marucci said. Celldex is already gearing up to broaden access to barzolvolimab. GlobeNewswire
Barzolvolimab targets the KIT receptor found on mast cells, the culprits behind itching and swelling. Celldex says its CSU program includes people with lingering symptoms despite H1 antihistamines, as well as those who haven’t seen results from advanced options such as omalizumab.
Celldex posted a net loss of $81.3 million, or $1.22 a share, in the fourth quarter, its regulatory filing showed. Full-year losses hit $258.8 million, driven by rising R&D spend. As of the end of 2025, the biotech held $518.6 million in cash, cash equivalents, and marketable securities—enough, management says, to fund operations into 2027. Celldex is set to bring Phase 2 data to the American Academy of Allergy, Asthma & Immunology (AAAI) annual meeting, running Feb. 27 to March 2. The company’s late-breaking poster is scheduled for March 1. Executives are calling 2026 a key year for clinical results.
Wednesday’s rally rode a wave of heavy volume, with rapid-fire trades and some sizable investors shifting gears on the headline. Come Thursday morning, the premarket drop told a different story—hesitation was clear, and many were sidestepping the open rather than chasing fresh swings.
With CSU, biologics tend to take over after antihistamines fail. Omalizumab keeps getting called the gold standard for tougher cases. Over at Celldex, they’re pushing barzolvolimab as a mast-cell targeted play, pointing investors to its late-stage development to make the case for its potential.
Rapid enrollment isn’t a free pass to clinical wins. Phase 3 can still miss its marks or flag new safety concerns. And if readouts slip, the cash runway shortens for a company spending heavily while waiting for product revenue.
Up next, the AAAAI meeting gets underway Friday, with Celldex scheduled to present a late-breaking poster on March 1. Looking beyond that, investors are watching for additional pipeline updates targeting 2026. The main focus, though, is on the highly anticipated Phase 3 CSU topline results expected in the fourth quarter of 2026.
